XML 92 R27.htm IDEA: XBRL DOCUMENT

Acquisition of Ceregene (Tables)

12 Months Ended

Dec. 31, 2013

Summary of Estimated Fair Value of Consideration Transferred

The following table summarizes the estimated fair value of the consideration transferred by Sangamo to the Ceregene stockholders on the Closing Date (in thousands):


Sangamo shares of common stock	$	1,200
Contingent earn-out		1,510

Total purchase consideration	$	2,710

Summary of Estimated Fair Value of Net Assets Acquired

The following table summarizes the estimated fair value of the net assets acquired as of the Closing Date (in thousands):


Cash and equivalents	$	79
Accounts receivable		22
Identifiable intangible assets		1,870
Goodwill		1,585

Total assets acquired		3,556
Deferred tax liability		(748	)
Accounts payable and accrued liabilities		(98	)

Total liabilities assumed		(846	)
Net assets acquired	$	2,710

Summary of Assets, Estimated Fair Values

A summary of these assets and estimated fair values at the Closing Date is as follows (in thousands):


	Value of Intangible Assets Acquired
CERE-110 for the treatment of Alzheimer’s disease	$	1,640
CERE-120 for the treatment of Parkinson’s disease		230

Total identifiable intangible assets	$	1,870

Schedule of Supplemental Pro Forma Information

This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2012, nor are they indicative of any future results.


	Year Ended December 31,
	2013			2012
	(In thousands except per share data)
Net loss	$	(30,997	)	$	(27,446	)
Basic net loss per share	$	(0.55	)	$	(0.52	)